New MRI contrast agents

Berlin, July 8, 2008 –The U.S. Food and Drug Administration (FDA) has approved Bayer Schering Pharma’s magnetic resonance imaging (MRI) contrast agent Primovist® (gadoxetate disodium) for the detection and characterization of liver lesions in adults with known or suspected focal liver disease. The product will be marketed in the United States under the name EOVIST®; it is currently marketed as Primovist outside the U.S. and as EOB Primovist in Japan. It is the first organ-specific MRI contrast agent to be approved in the U.S. for over a decade. Bayer plans to make EOVIST available to customers in the U.S. in the summer of 2008.

“Primovist not only offers the unique benefit of being able to simultaneously detect, locate and distinguish various types of liver lesions, but also helps to guide and follow-up on treatment decisions, as it enables radiologists to identify even tiny pathological liver lesions,” said Dr. Gunnar Riemann, Member of the Board of Management of Bayer Schering Pharma AG, responsible for the company’s Business Units. “Bayer is now in the unique position of offering Primovist for diagnosing patients with liver cancer and Nexavar for treating hepatocellular carcinoma – the most common form of liver cancer.”

More info here

  • Doreen Schröder
    Telefon: +49 30 468-11399
    Fax: +49 30 468-16710
  • E-Mail

2 thoughts on “New MRI contrast agents

  1. I am studying for my MRI exam (which I take in a couple days) and I have a few questions. It has been one year since I had my MRI classes and I’m not sure if some of the information I learned has changed. I have sources that are giving me conflicting information!

    1. Does the FDA have contraindications for Gad? I was tought that there is not any, however just cautions for preg. or lactating females and also for sickle cell patients.

    2. Current FDA limits for Clinical static magnetic fields for children/adults?

    3. Current limit for rate of change of time varying magnetic fields?

    4. What are the SAR levels?

    Please feel free to E-mail me
    Thanks for your time:)

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s